RxDoctor Payments Data

Vivek Rudrapatna, MD

Internal Medicine · Salinas, CANPI 1740477074

Payments from drug & device makers

$358,497in general payments, 2019–2025

Across 428 payments — averaging $837.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$344K
  • Ironwood Pharmaceuticals, Inc$7K
  • AbbVie$1K
  • Amgen$820
  • Novo Nordisk$757
  • Pfizer$667
  • plus $4K from 36 others

What the payments were for

  • Consulting fees$6,50046%
  • Food & beverage$7,72354%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$358,497 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$507,120
Medicare patients
1,308
Services billed
13,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin238$227,150
EliquisApixaban191$121,354
TrulicityDulaglutide66$96,106
TradjentaLinagliptin101$64,170
OzempicSemaglutide44$45,770
FarxigaDapagliflozin Propanediol33$27,929
JanuviaSitagliptin Phosphate22$27,757
RybelsusSemaglutide15$24,024
LinzessLinaclotide14$22,156
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,359
JanumetSitagliptin Phos/Metformin Hcl19$16,608
Breo ElliptaFluticasone/Vilanterol27$13,371
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$12,156
XareltoRivaroxaban19$12,076
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog44$10,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$38$291,320339 claims
PfizerEliquis$667$121,354191 claims
Lilly USA, LLCTrulicity$549$96,10666 claims
Novo NordiskOzempic, Rybelsus$757$69,79459 claims
MerckJanuvia, Janumet$130$44,36541 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$593$41,44977 claims
AstraZenecaFarxiga$251$27,92933 claims
AbbVieLinzess$1,279$22,15614 claims
Johnson & JohnsonXarelto$147$12,07619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →